GINWA(SH:600080) Hua Xia Shi Bao·2025-05-28 00:20Core Viewpoint - Jin Hua Co., Ltd. is facing unprecedented challenges due to the investigation of its chairman, Xing Yajiang, for violations related to stock disclosure, which has raised concerns about the company's governance and operational stability [3][4][5]. Group 1: Governance Issues - Xing Yajiang has been investigated twice within six months for information disclosure violations, indicating systemic governance flaws within the company [5][6]. - The company has reported over 20 instances of disciplinary violations from 2020 to 2025, highlighting ongoing compliance issues [5]. - The chairman's repeated legal troubles may damage investor trust and lead to stricter regulatory scrutiny, potentially resulting in administrative penalties and increased legal risks [6]. Group 2: Financial Performance - Jin Hua Co., Ltd. has exhibited significant fluctuations in its financial performance, with net profits alternating between gains and losses from 2020 to 2024, reflecting a lack of stable revenue generation capabilities [7][10]. - In 2024, the company reported a revenue of 585.46 million yuan, a 3.55% increase year-on-year, and a net profit of 74.61 million yuan, marking a return to profitability [9]. - The profit increase was largely driven by asset disposal gains, specifically the sale of a hotel, which contributed 34.33 million yuan to net profit, masking the underlying issues in core business performance [7][8]. Group 3: Recent Trends - In the first quarter of 2025, the company experienced a revenue decline of 7.31% year-on-year, with net profit dropping by 94.93%, indicating ongoing struggles despite a 151.79% increase in net profit after excluding non-recurring items [13][14]. - The core pharmaceutical business showed a slight revenue increase of 4.43%, primarily driven by a 9.11% growth in orthopedic products, while the hotel segment saw a drastic revenue drop due to the earlier asset disposal [14].